William Ackman's SPAC Confirms Talks To Buy 10% Of Vivendi-owned UMG For About $4 Bln - Quick Facts

Hedge-fund billionaire William Ackman's special-purpose acquisition company, Pershing Square Tontine Holdings Ltd. (PSTH), confirmed Friday that it is in discussions with Vivendi S.E. (VIV.L,VIVEF.PK) to acquire 10% of the outstanding ordinary shares of Universal Music Group B.V. or "UMG" for about $4 billion, representing an enterprise value of 35 billion euros for UMG.

Unlike most SPAC business combinations, PSTH and UMG will not combine into one company following the transaction, Pershing Square said in a statement.

Following PSTH's acquisition of the UMG Shares, UMG will complete its previously announced listing on Euronext Amsterdam in the third quarter of 2021.

Once the Listing is complete, PSTH will distribute the UMG Shares directly to PSTH's shareholders in a transaction registered with the Securities and Exchange Commission.

PSTH intends to remain listed on the NYSE, with $1.5 billion of cash after the distribution of UMG shares, and to seek new business combination partner.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT